ESMO Congress | Conference

Case Series Highlights Afatinib Activity in NRG1+ Cancers

September 30th 2019

A case series presented at the 2019 ESMO Congress highlighted the activity of afatinib in patients with NRG1-positive tumors.

Positive Abemaciclib Data Emerge for Chinese Women With HR+ Breast Cancer

September 30th 2019

A population of predominantly Chinese women with advanced hormone receptor–positive/HER2-negative breast cancer obtained significant benefits from treatment with the CDK4/6 inhibitor abemaciclib and endocrine therapy.

Atezolizumab/Chemo Improves PFS in Metastatic Urothelial Cancer

September 30th 2019

The first-line combination of atezolizumab (Tecentriq) and chemotherapy led to an improvement in median progression-free survival compared with placebo/chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

ClarIDHy Ivosidenib Data Practice-Changing for Advanced Cholangiocarcinoma

September 30th 2019

Treatment with ivosidenib reduced the risk of progression or death by 63% compared with placebo for pretreated patients with IDH1-mutant advanced cholangiocarcinoma.

Olaparib Doubles rPFS in Heavily Pretreated HRR+ mCRPC

September 30th 2019

Olaparib improved radiographic progression-free survival compared with physician's choice of abiraterone acetate or enzalutamide in men with heavily pretreated metastatic castration-resistant prostate cancer with homologous recombination repair (HRR) gene alterations.

Larotrectinib Continues to Show High Efficacy, Low Toxicity in TRK Fusion-Positive Cancers

September 29th 2019

The tumor-agnostic TRK inhibitor larotrectinib (Vitrakvi) demonstrated marked antitumor efficacy, including objective responses that often persisted for years, and a favorable safety profile.

Dr. Slamon on OS Results of the MONALEESA-3 Trial in HR+/HER2- Breast Cancer

September 29th 2019

Dennis J. Slamon, MD, PhD, director, Clinical/Translational Research, Revlon/University of California, Los Angeles (UCLA) Women's Cancer Research Program, Jonsson Comprehensive Cancer Center, UCLA, discusses the overall survival results of the phase III MONALEESA-3 trial in hormone receptor-positive, HER2-negative breast cancer.

Dr. Gonzalez-Martin on the Results of the PRIMA Trial in Ovarian Cancer

September 29th 2019

Antonio Gonzalez-Martin, MD, co-director, Department of Medical Oncology, Clinica Universidad de Navarra, discusses the results of the phase III PRIMA trial in advanced ovarian cancer.

Selpercatinib Shows Strong ORR in Thyroid Cancer, FDA Submission Expected

September 29th 2019

The highly selective RET inhibitor selpercatinib (formally LOXO-292) demonstrated robust objective response rates for patients with RET-mutant medullary thyroid cancer and in those with other RET fusion-positive thyroid cancer.

PD-L1 Assays Demonstrate

September 29th 2019

An exploratory biomarker substudy of Impassion130 demonstrated clinical activity of atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane) in a subgroup of patients with triple-negative breast cancer who had immune cell PD-L1 expression by the SP142 immunohistochemistry assay, regardless of the site of the tumor sample.

Abemaciclib/Fulvestrant Improves Survival in HR+ Advanced Breast Cancer

September 29th 2019

The addition of the CDK4/6 inhibitor abemaciclib (Verzenio) to fulvestrant (Faslodex) led to a median 9.4-month overall survival benefit compared with fulvestrant with placebo in patients with hormone receptor–positive, HER2-negative advanced breast cancer who progressed on prior endocrine therapy.

Atezolizumab Combo Confirmed as Frontline Standard in Advanced Small Cell Lung Cancer

September 29th 2019

With follow-up of nearly 2 years, the addition of atezolizumab to first-line carboplatin plus etoposide for the treatment of extensive stage small cell lung cancer continues to demonstrate improved overall survival compared with placebo plus CP/ET.

Abemaciclib Activity Extends to HR+/HER2+ Breast Cancer

September 29th 2019

Adding abemaciclib (Verzenio) and endocrine therapy to trastuzumab (Herceptin) improved progression-free survival in advanced hormone receptor-positive, HER2-positive breast cancer versus trastuzumab and chemotherapy.

Ribociclib/Fulvestrant Combo Improves OS in Advanced HR+ Breast Cancer

September 29th 2019

The combination of ribociclib and fulvestrant led to an approximate 28% reduction in the risk of death compared with placebo and fulvestrant in postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer.

Neoadjuvant Pembrolizumab Combo Prolongs pCR in Phase III TNBC Study

September 29th 2019

Neoadjuvant treatment with the combination of pembrolizumab and chemotherapy extended pathological complete response rates by 13.6 percentage points compared with chemotherapy alone for patients with early triple-negative breast cancer.

Trilaciclib Delivers "Unexpected" Survival Boost in TNBC

September 29th 2019

The investigational CDK4/6 inhibitor trilaciclib unexpectedly improved survival in metastatic triple-negative breast cancer despite failing to meet a safety-related primary endpoint.

Experts Highlight Anticipated Research to Be Revealed at ESMO 2019

September 29th 2019

OncLive interviewed experts at the State of the Science Summits™ in September 2019 on anticipated research to be presented at the 2019 ESMO Congress.

Adding Atezolizumab May Improve Outcomes in HER2+ Breast Cancer With PD-L1 Expression

September 28th 2019

A numerical improvement in overall survival was realized with the addition of atezolizumab (Tecentriq) to ado-trastuzumab emtansine (T-DM1; Kadcyla) compared with T-DM1 alone.

Dr. Ramalingam on the OS Results of the FLAURA Trial in EGFR-Mutant NSCLC

September 28th 2019

Suresh S. Ramalingam, MD, discusses the overall survival (OS) results of the phase III FLAURA trial in patients with EGFR-mutant non–small cell lung cancer (NSCLC).

Dr. Weber on the Updated Analysis of the CheckMate-238 Trial in Melanoma

September 28th 2019

Jeffrey S. Weber, MD, PhD, discusses the updated analysis of the phase III CheckMate-238 trial in patients with resected stage III/IV melanoma.